← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
prasugrel
B01AC22
Adult Dosing
- Loading dose: 60mg orally once
- Maintenance dose: 10mg orally once daily
- Reduced dose for patients with low body weight (<60kg): 5mg orally once daily
Pediatric Dosing
- Not established for patients under 18 years old
Indications
- Acute coronary syndrome (ACS) with planned percutaneous coronary intervention (PCI)
- Reduce the rate of myocardial infarction and stroke in patients with ACS
Mechanism of Action
- Inhibits platelet activation and aggregation by selectively and irreversibly binding to the P2Y12 receptor
- Blocks adenosine diphosphate (ADP) from inducing platelet aggregation
Contraindications
- Active bleeding
- History of transient ischemic attack or stroke
- Hypersensitivity to prasugrel or any component of the formulation
Adverse Reactions
- Bleeding (including life-threatening bleeding)
- Hypotension
- Thrombocytopenia
- Headache
- Dizziness
- Fatigue
Drug Interactions
- Aspirin: increased risk of bleeding
- Warfarin: increased risk of bleeding
- Fibrinolytics: increased risk of bleeding
- Other antiplatelet agents: increased risk of bleeding
Curated Content: Needs Vetting Before Put to Clinical Use